Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer
暂无分享,去创建一个
[1] J. Massagué,et al. SMADs: mediators and regulators of TGF-β signaling , 1998 .
[2] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[3] D. Horsfall,et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Kathleen R. Cho,et al. DPC4 gene in various tumor types. , 1996, Cancer research.
[5] S. Hughes,et al. Activation of the c-ski oncogene by overexpression , 1991, Journal of virology.
[6] W. Bodmer,et al. Screening SMAD1,SMAD2, SMAD3, andSMAD5 for germline mutations in juvenile polyposis syndrome , 1999, Gut.
[7] E. Gabrielson,et al. The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma. , 1999, Cancer research.
[8] H. Hollema,et al. Structural alterations of transforming growth factor‐β receptor genes in human cervical carcinoma , 1999, International journal of cancer.
[9] N. Nomura,et al. Expression of the c-ski proto-oncogene in human melanoma cell lines. , 1993, Melanoma research.
[10] K. Irie,et al. The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3 , 1998, Nature.
[11] A. Roberts,et al. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. , 1998, Genes & development.
[12] K. Miyazono,et al. Smad6 inhibits signalling by the TGF-β superfamily , 1997, Nature.
[13] J. Willson,et al. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells , 1994 .
[14] A. Klibanski,et al. Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors. , 1999, The Journal of clinical endocrinology and metabolism.
[15] Luzhe Sun,et al. Reduced Expression of Transforming Growth Factor β Type I Receptor Contributes to the Malignancy of Human Colon Carcinoma Cells* , 1996, The Journal of Biological Chemistry.
[16] R. Lotan,et al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. , 1996, Cancer research.
[17] Qiang Zhou,et al. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. , 1999, Genes & development.
[18] J. Massagué. TGF-beta signal transduction. , 1998, Annual review of biochemistry.
[19] N. Wake,et al. Mutation analysis of the Smad3 gene in human ovarian cancers. , 1999, International journal of oncology.
[20] R. Weinberg,et al. Interaction of the Ski Oncoprotein with Smad3 Regulates TGF-β Signaling , 1999 .
[21] R. Coffey,et al. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[22] T. Kouzarides. Histone acetylases and deacetylases in cell proliferation. , 1999, Current opinion in genetics & development.
[23] R. Wieser,et al. Mutational analysis of the tumor suppressor Smad2 in acute lymphoid and myeloid leukemia , 1998, Leukemia.
[24] J. Massagué,et al. TGF- SIGNAL TRANSDUCTION , 1998 .
[25] K. Kinzler,et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. , 1995, Cancer research.
[26] J. Yokota,et al. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. , 1997, Cancer research.
[27] K. Kinzler,et al. Lessons from Hereditary Colorectal Cancer , 1996, Cell.
[28] G. Nucifora. The EVI1 gene in myeloid leukemia , 1997, Leukemia.
[29] H. Ostrer,et al. TβR-I(6A) Is a Candidate Tumor Susceptibility Allele , 1999 .
[30] A. Green,et al. Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. , 1999, International journal of oncology.
[31] T. Mitsudomi,et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. , 1996, Cancer research.
[32] K. Kinzler,et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. , 1999, Cancer research.
[33] D. Dillon,et al. The molecular biology of breast cancer: accelerating clinical applications. , 1998, Critical reviews in oncogenesis.
[34] S. Nishizuka,et al. MAD‐related Genes on 18q21.1, Smad2 and Smad4, Are Altered Infrequently in Esophageal Squamous Cell Carcinoma , 1997, Japanese journal of cancer research : Gann.
[35] H. Friess,et al. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. , 1999, Biochemical and biophysical research communications.
[36] K. Luo,et al. Negative Feedback Regulation of TGF-β Signaling by the SnoN Oncoprotein , 1999 .
[37] R. Derynck,et al. Transcriptional Activators of TGF-β Responses: Smads , 1998, Cell.
[38] Z. Hall. Cancer , 1906, The Hospital.
[39] R. Hruban,et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. , 1998, Cancer research.
[40] C. Heldin,et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. , 1998, Biochemical and biophysical research communications.
[41] D. Welch. Transforming growth factor β stimulates mamary adenocarcinoma cell invasion and metastasis potential , 1990 .
[42] Adriana,et al. Resistance to Transforming Growth Factor 1 and Activin Due to Reduced Receptor Expression in Human Breast Tumor Cell Lines ’ , 2005 .
[43] C. Marshall,et al. How do small GTPase signal transduction pathways regulate cell cycle entry? , 1999, Current opinion in cell biology.
[44] A. Andrén-sandberg,et al. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer , 1999, Genes, chromosomes & cancer.
[45] S. Ishii,et al. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. , 1999, Genes & development.
[46] Y. Yazaki,et al. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. , 1995, Oncogene.
[47] J. Kleeff,et al. Transfection of the type I TGF‐β receptor restores TGF‐β responsiveness in pancreatic cancer , 1998 .
[48] H. Taguchi,et al. Analysis of the Smad2 gene in hematological malignancies , 1998, Leukemia.
[49] H. Beug,et al. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis , 1998, Current Biology.
[50] S. Horiike,et al. Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-beta receptor type II gene mutation. , 1996, Leukemia.
[51] J. Massagué,et al. A Smad Transcriptional Corepressor , 1999, Cell.
[52] D. Slamon,et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] C. Heldin,et al. Expression of Smad proteins in human colorectal cancer , 1999, International journal of cancer.
[54] K. Miyazono,et al. Induction of Smad6 mRNA by bone morphogenetic proteins. , 1998, Biochemical and biophysical research communications.
[55] H. Lodish,et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. , 1999, Blood.
[56] Y. Yatabe,et al. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. , 1996, Cancer research.
[57] J. Massagué,et al. Smad4/DPC4 Silencing and Hyperactive Ras Jointly Disrupt Transforming Growth Factor-β Antiproliferative Responses in Colon Cancer Cells* , 1999, The Journal of Biological Chemistry.
[58] J. Willson,et al. Expression of transforming growth factor‐β receptor type II and tumorigenicity in human breast adenocarcinoma MCF‐7 cells , 1998 .
[59] D. Alberts,et al. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. , 1996, British Journal of Cancer.
[60] Anita B. Roberts,et al. Tumor suppressor activity of the TGF-β pathway in human cancers , 1996 .
[61] A. Kilbey,et al. Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[62] C. Heldin,et al. Specificity, diversity, and regulation in TGF‐β superfamily signaling , 1999 .
[63] L. Aaltonen,et al. SMAD genes in juvenile polyposis , 1999, Genes, chromosomes & cancer.
[64] N. Nomura,et al. Isolation of human cDNA clones of ski and the ski-related gene, sno. , 1989, Nucleic acids research.
[65] H. Moses,et al. Transforming Growth Factor β and Cell Cycle Regulation , 1995 .
[66] K. Miyazono,et al. c-Ski Acts as a Transcriptional Co-repressor in Transforming Growth Factor-β Signaling through Interaction with Smads* , 1999, The Journal of Biological Chemistry.
[67] J. Barber. Medical genetics: advances in brief , 1995 .
[68] M. Nakajima,et al. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[69] Y. Yazaki,et al. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. , 1998, Blood.
[70] Irene L Andrulis,et al. MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma , 1996, Cell.
[71] R. Weinberg,et al. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[72] Mohammed A. Khan,et al. Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β , 1997, Oncogene.
[73] H. Beug,et al. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.
[74] J. Massagué,et al. A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. , 1999, Genes & development.
[75] H. Friess,et al. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer , 1999, Oncogene.
[76] M. Reiss,et al. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. , 1998, Cancer research.
[77] Kathleen R. Cho,et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. , 1995, Cancer research.
[78] S. Kern,et al. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. , 1996, Cancer research.
[79] A. V. van Kessel,et al. Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts , 1996, International journal of cancer.
[80] Y. Yuasa,et al. Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. , 1998, Cancer letters.
[81] D. Demetrick,et al. Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast. , 1996, Biochemical and biophysical research communications.
[82] C. Heldin,et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.
[83] M. Reiss,et al. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. , 1993, Critical reviews in oncogenesis.
[84] R Wieser,et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.
[85] Takeo Iwama,et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis , 1999, Oncogene.
[86] Y. Nagamachi,et al. Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers. , 1998, Oncology reports.
[87] C. Niehrs,et al. Silencing of TGF-β signalling by the pseudoreceptor BAMBI , 1999, Nature.
[88] R. L. Baldwin,et al. Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition , 1996, International journal of cancer.
[89] H. Kuwano,et al. No mutations of the Smad2 gene in human sporadic gastric carcinomas. , 1999, Japanese journal of clinical oncology.
[90] Mansoor M Ahmed,et al. Novel mutations in the polyadenine tract of the transforming growth factor β type II receptor gene are found in a subpopulation of human pancreatic adenocarcinomas , 1998, Genes, chromosomes & cancer.
[91] Scott E. Kern,et al. Mad-related genes in the human , 1996, Nature Genetics.
[92] J. Slingerland,et al. Transforming growth factor-β and breast cancer: Cell cycle arrest by transforming growth factor-β and its disruption in cancer , 2000, Breast Cancer Research.
[93] H. Kuwano,et al. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. , 1999, International journal of oncology.
[94] O. Cussenot,et al. Expression and mutational analysis of the MADR2/smad2 gene in human prostate cancer , 1999, The Prostate.
[95] Scott E. Kern,et al. DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.
[96] C. Benz,et al. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. , 1989, Cancer research.
[97] K. Kinzler,et al. Frequency of Smad gene mutations in human cancers. , 1997, Cancer research.
[98] H. Lodish,et al. Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia , 1997 .
[99] J. Massagué,et al. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. , 1998, Genes & development.
[100] K. Naito,et al. Endometrial expression of cellular protooncogene c‐ski and its regulation by estradiol‐17β , 1999, FEBS letters.
[101] Yusuke Nakamura,et al. Mapping of a Breast Cancer Tumor Suppressor Gene Locus to a 4‐cM Interval on Chromosome 18q21 , 1997, Japanese journal of cancer research : Gann.
[102] J. Wrana,et al. The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.
[103] F. Pouliot,et al. Expression profile of agonistic Smads in human breast cancer cells: Absence of regulation by estrogens , 1999, International journal of cancer.